The purpose of the study was to assess the efficacy and tolerance of the beta1-selective beta-adrenoceptor-blocking agent @entity2179 in @entity1 with @entity5749 . A total of 236 outpatients (158 male and 78 female) over 21 years of age (mean age of 57 years and 60 years for @entity1 and @entity1 , respectively) were included in an open trial of 4 weeks duration. A total of 32.5% of the @entity1 were smokers. After a washout period of at least 1 week, @entity1 were initially treated with 10 mg of @entity2179 o.d. for 2 weeks, after which the dose could be adjusted to 5, 15, or 20 mg in accordance with clinical criteria (efficacy, tolerance). Eighty-eight percent of the @entity1 were maintained on 10 mg of @entity2179 . The frequency of @entity951 was reduced in 89% of all @entity1 : 56% became free of @entity951 . There were no differences in response as related to age and smoking habits. @entity2179 was well tolerated. Beta-blocker-specific side effects were observed in 12 @entity1 (5.1%). In conclusion, @entity2179 administered once daily appears to be an effective and safe antianginal agent.

@entity2179 in the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity951 :: ('MESH:D000787', 'Disease') :: ['angina attacks'] @entity5749 :: ('MESH:D060050', 'Disease') :: ['chronic stable angina pectoris'] @entity2179 :: ('MESH:D017298', 'Chemical') :: ['bisoprolol', 'Bisoprolol']
@entity5749 :: (MESH:D060050,Disease) :: ['chronic stable angina pectoris']
